These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 23803018)
1. Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Wei GL; Huang XE; Huo JG; Wang XN; Tang JH Asian Pac J Cancer Prev; 2013; 14(5):2703-6. PubMed ID: 23803018 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of Loubo® (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Deng QQ; Huang XE; Ye LH; Lu YY; Liang Y; Xiang J Asian Pac J Cancer Prev; 2013; 14(1):413-7. PubMed ID: 23534764 [TBL] [Abstract][Full Text] [Related]
3. Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Huang XE; Tian GY; Cao J; Xu X; Lu YY; Wu XY; Liu J; Shi L; Xiang J Asian Pac J Cancer Prev; 2014 Jan; 14(11):6663-7. PubMed ID: 24377585 [TBL] [Abstract][Full Text] [Related]
4. Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC). Liu J; Huang XE; Feng JF Asian Pac J Cancer Prev; 2014; 15(16):6587-90. PubMed ID: 25169492 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Wu XY; Huang XE; You SX; Lu YY; Cao J; Liu J Asian Pac J Cancer Prev; 2013; 14(3):2019-22. PubMed ID: 23679311 [TBL] [Abstract][Full Text] [Related]
7. Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study. Zhang DS; Jin Y; Luo HY; Wang ZQ; Qiu MZ; Wang FH; Li YH; Xu RH Br J Cancer; 2015 Jan; 112(2):266-70. PubMed ID: 25474247 [TBL] [Abstract][Full Text] [Related]
8. A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer. Wu XY; Huang XE; Cao J; Shi L; Xu X; Qian ZY Asian Pac J Cancer Prev; 2014; 15(14):5941-4. PubMed ID: 25081726 [TBL] [Abstract][Full Text] [Related]
9. Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy. Zhang Y; Zhao L; Huang P; Wu J; Wang F; Huang Y; Zhang L Cancer Chemother Pharmacol; 2012 Oct; 70(4):611-5. PubMed ID: 22903536 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of irinotecan in combination with cisplatin as second-line chemotherapy in patients with metastatic or locally advanced gastric cancer. Shen WC; Yang TS; Hsu HC; Chen JS Chang Gung Med J; 2011; 34(6):590-8. PubMed ID: 22196061 [TBL] [Abstract][Full Text] [Related]
12. A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. Chen JS; Chao Y; Bang YJ; Roca E; Chung HC; Palazzo F; Kim YH; Myrand SP; Mullaney BP; Shen LJ; Linn C Anticancer Drugs; 2010 Sep; 21(8):777-84. PubMed ID: 20634689 [TBL] [Abstract][Full Text] [Related]
13. Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. Kim YH; Chung HC; Kang WK; Park SR; Kim CS; Kim TY; Shin SW; Park BJ; Cha SJ; Bang YJ Cancer Chemother Pharmacol; 2008 Jul; 62(2):263-70. PubMed ID: 17960386 [TBL] [Abstract][Full Text] [Related]
14. Pemetrexed in advanced colorectal cancer. Louvet C; de Gramont A Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):56-62. PubMed ID: 15655939 [TBL] [Abstract][Full Text] [Related]
15. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer]. Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326 [TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. Miller DS; Blessing JA; Krasner CN; Mannel RS; Hanjani P; Pearl ML; Waggoner SE; Boardman CH J Clin Oncol; 2009 Jun; 27(16):2686-91. PubMed ID: 19332726 [TBL] [Abstract][Full Text] [Related]
17. Phase I trial of vinflunine and pemetrexed in refractory solid tumors. Sanoff HK; Davies J; Walko C; Buie L; Chiu WK; Ivanova A; O'Neil B; Stinchcombe TE; Keller K; Dees EC Invest New Drugs; 2011 Feb; 29(1):131-6. PubMed ID: 19830387 [TBL] [Abstract][Full Text] [Related]
18. Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study. Llombart-Cussac A; Theodoulou M; Rowland K; Clark RS; Nakamura T; Carrasco E; Cruciani G Clin Breast Cancer; 2006 Dec; 7(5):380-5. PubMed ID: 17239262 [TBL] [Abstract][Full Text] [Related]
19. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830 [TBL] [Abstract][Full Text] [Related]
20. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Miles DW; Smith IE; Coleman RE; Calvert AH; Lind MJ Eur J Cancer; 2001 Jul; 37(11):1366-71. PubMed ID: 11435066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]